About this item:

31 Views | 12 Downloads

Author Notes:

Danielle L. Peters, danielle.peters@ntc-cnrc.gc.ca

Conceptualization, D.L.P. and W.C.; methodology, D.L.P. and C.M.D.; validation, D.L.P., J.J.D. and W.C.; formal analysis, D.L.P.; investigation, D.L.P., G.H., C.M.D., H.Z., S.H. and P.N.R.; resources, W.C.; data curation, D.L.P., C.M.D., G.H. and S.H.; writing—original draft preparation, D.L.P.; writing—review and editing, D.L.P., W.C., G.H. and C.M.D.; supervision, D.L.P., P.N.R., E.L. and W.C.; project administration, D.L.P. and W.C.; funding acquisition, W.C. All authors have read and agreed to the published version of the manuscript.

The authors would like to thank Howard Xu (California State University, Los Angeles) and Ayush Kumar (University of Manitoba) for providing the A. baumannii LAC-4 and AB030 strains, respectively, and Robert Delatolla from the University of Ottawa for the sewage samples. The following reagent was obtained through BEI Resources, NIAID, NIH: Acinetobacter baumannii MRSN Diversity Panel, NR-52248, provided by the Multidrug-Resistant Organism Repository and Surveillance Network (MRSN) at the Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA. We also wish to acknowledge Karen Zhao for her help with reagents and media in part of this study.

The authors declare no conflict of interest.


Research Funding:

This study was partially supported by the National Research Council (NRC) Canada’s Ideation Small Team Project (National Program Office) (DLP and WC), the Natural Sciences and Engineering Research Council of Canada Discovery grant (238414-2018)(JD), and the Department of Veterans Affairs awards I01BX001725 and IK6BX004470 (PNR).


  • Science & Technology
  • Life Sciences & Biomedicine
  • Virology
  • bacteriophage
  • Acinetobacter baumannii
  • phage therapy
  • lytic phage
  • antimicrobial resistance
  • phage
  • T4-like phage
  • Acinetobacter phage

Characterization of Virulent T4-Like Acinetobacter baumannii Bacteriophages DLP1 and DLP2


Journal Title:



Volume 15, Number 3


Type of Work:

Article | Final Publisher PDF


The world is currently facing a global health crisis due to the rapid increase in antimicrobial-resistant bacterial infections. One of the most concerning pathogens is Acinetobacter baumannii, which is listed as a Priority 1 pathogen by the World Health Organization. This Gram-negative bacterium has many intrinsic antibiotic resistance mechanisms and the ability to quickly acquire new resistance determinants from its environment. A limited number of effective antibiotics against this pathogen complicates the treatment of A. baumannii infections. A potential treatment option that is rapidly gaining interest is “phage therapy”, or the clinical application of bacteriophages to selectively kill bacteria. The myoviruses DLP1 and DLP2 (vB_AbaM-DLP_1 and vB_AbaM-DLP_2, respectively) were isolated from sewage samples using a capsule minus variant of A. baumannii strain AB5075. Host range analysis of these phages against 107 A. baumannii strains shows a limited host range, infecting 15 and 21 for phages DLP1 and DLP2, respectively. Phage DLP1 has a large burst size of 239 PFU/cell, a latency period of 20 min, and virulence index of 0.93. In contrast, DLP2 has a smaller burst size of 24 PFU/cell, a latency period of 20 min, and virulence index of 0.86. Both phages show potential for use as therapeutics to combat A. baumannii infections.

Copyright information:

© 2023 by the authors.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote